Rare Disease Treatment Market Estimated to Flourish by 2016 - 2024 - Persistence Market Research
Rare disease drug development was so far neglected or given less importance due to lower profitability as there are less number of patients deemed eligible for treatment by such drugs. However, incentives offered by Orphan Drug Act (ODA) in the U.S. and EU such as tax reduction and market exclusivity is expected to boost the global market for rare disease treatment. Since, the enactment of ODA, FDA has approved more than 480 orphan drugs and 47% of new drugs approved...
View full press release